GlassScriptPhysician profile
Arash Zarrin
NPI 1407351729
$1,588.31
in general payments reported to CMS, 2019-2025
23 companies · $748 in 2025
The $748 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $304 · 2023: $210 · 2024: $327 · 2025: $748.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,284.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $362.45 | 2022-2024 | Resolution 360 Clip |
| Abbvie INC. | $188.51 | 2024-2025 | |
| Janssen Biotech, INC. | $141.35 | 2024-2025 | Tremfya |
| Intercept Pharmaceuticals, INC. | $114.23 | 2023 | Ocaliva |
| Pfizer INC. | $90.69 | 2025 | |
| Madrigal Pharmaceuticals | $71.95 | 2024-2025 | Rezdiffra, Resmetirom |
| Aimmune Therapeutics, INC. | $68.97 | 2025 | Vowst, Zenpep |
| Takeda Pharmaceuticals U.S.A., INC. | $66.26 | 2025 | Entyvio |
| Ardelyx, INC. | $58.11 | 2024-2025 | Ibsrela |
| Novo Nordisk INC | $50.00 | 2025 | Wegovy |
| Genzyme Corporation | $48.50 | 2025 | |
| Phathom Pharmaceuticals, INC. | $45.89 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.50 | 2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $39.35 | 2022-2024 | Dificid, Zinplava |
| Medtronic, INC. | $37.94 | 2024 | Bravo |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $28.41 | 2025 | Omvoh |
| Qol Medical, LLC | $23.80 | 2024 | Sucraid |
| Redhill Biopharma INC. | $22.81 | 2022 | |
| Celgene Corporation | $21.80 | 2024 | Zeposia |
| Janssen Pharmaceuticals, INC | $18.96 | 2022 | |
| Organon LLC | $17.66 | 2025 | Hadlima |
| Capsovision, INC. | $15.39 | 2024 | Capsocam Plus |
| Fresenius Kabi USA, LLC | $14.78 | 2024 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arash Zarrin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.